In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback